# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $59 to $60.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
The gross proceeds from the offering are expected to be approximately $230 million before deducting underwriting discounts and ...
Biohaven Ltd. (NYSE:BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-chan...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300...
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $61 price target.